A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY

Autor:	Michael S. Weiss, Ian W. Flinn, Anthony R. Mato, James A. Reeves, Nicole Lamanna, E. Luning Prak, Colleen Dorsey, Stephen J. Schuster, N.M. LaRatta, Frederick Lansigan, John M. Pagel, Gustavo Fonseca, Hari P. Miskin, Bruce D. Cheson, Paul M. Barr, Suman Kambhampati, Hanna Weissbrot, Jakub Svoboda, Patricia Y. Tsao, Peter Sportelli, Jeffrey J. Pu, Alan P Skarbnik, Andrea Sitlinger, Dana Paskalis, Danielle M. Brander, Jaqueline C. Barrientos
Rok vydání:	2019
Předmět:	Oncology Cancer Research medicine.medical_specialty biology business.industry Chronic lymphocytic leukemia Phases of clinical research Hematology General Medicine medicine.disease Internal medicine medicine biology.protein Bruton's tyrosine kinase In patient business PI3K/AKT/mTOR pathway
Zdroj:	Hematological Oncology. 37:88-89
ISSN:	0278-0232
DOI:	10.1002/hon.56_2629
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::febcba62422904b919361c94f2003ecc https://doi.org/10.1002/hon.56_2629 Zobrazit plný text záznamu Plný text